Alasdair Coles
University of Cambridge
H-index: 59
Europe-United Kingdom
Top articles of Alasdair Coles
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Bexarotene leads to durable improvements in visual evoked potential latency: A follow-up study of the Cambridge Centre for Myelin Repair One trial | Multiple Sclerosis Journal | Christopher E McMurran Trisha Mukherjee J William L Brown Alasdair J Coles Nick G Cunniffe | 2024/3/1 |
Comparing the Pathology, Clinical, and Demographic Characteristics of Younger and Older‐Onset Multiple Sclerosis | Annals of Neurology | Sarah Knowles Rod Middleton Benjamin Cooze Ildiko Farkas Yeung Yeung Leung | 2024/3 |
Brain injury in COVID-19 is associated with dysregulated innate and adaptive immune responses (vol 145, pg 4097, 2022) | Brain | Edward J Needham Alexander L Ren Richard J Digby Emma J Norton Soraya Ebrahimi | 2022/11/1 |
Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis … | BMJ open | Gavin Brittain Jennifer Petrie Kate EM Duffy Rachel Glover Katie Hullock | 2024/2/1 |
Addressing ethnic disparities in neurological research in the United Kingdom: an example from the prospective multicentre COVID-19 Clinical Neuroscience Study | Clinical Medicine | Daniel J van Wamelen Silvia Rota Monika Hartmann Naomi H Martin Ali M Alam | 2024/4/19 |
Protocol: Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple … | BMJ Open | Gavin Brittain Jennifer Petrie Kate EM Duffy Rachel Glover Katie Hullock | 2024 |
Author Correction: Para-infectious brain injury in COVID-19 persists at follow-up despite attenuated cytokine and autoantibody responses | nature communications | Benedict D Michael Cordelia Dunai Edward J Needham Kukatharmini Tharmaratnam Robyn Williams | 2024/4/4 |
Visual outcome measures in clinical trials of remyelinating drugs | Gioia Riboni-Verri Benson S Chen Christopher E McMurran Gregory J Halliwell J William L Brown | 2024 | |
Autologous haematopoietic stem cell transplantation for immune-mediated neurological diseases: what, how, who and why? | Rheumatology | Joao R Lima-Junior Lucas CM Arruda Maynara S Goncalves Juliana BE Dias Daniela A Moraes | 2021/12/1 |
Para-infectious brain injury in COVID-19 persists at follow-up despite attenuated cytokine and autoantibody responses | Nature communications | Benedict D Michael Cordelia Dunai Edward J Needham Kukatharmini Tharmaratnam Robyn Williams | 2023/12/22 |
Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study | Therapeutic Advances in Neurological Disorders | Alasdair J Coles Anat Achiron Anthony Traboulsee Barry A Singer Carlo Pozzilli | 2023/9 |
Author response to Dr. Jagannadha Avasarala | Alasdair J Coles | 2023/3/30 | |
Novel paraneoplastic mechanism for cerebellar ataxia in Erdheim-Chester disease | BMJ Case Reports CP | Amir Rafati Fard Juliet Thornton Alasdair Coles | 2023/9/1 |
Chasing MOG antibodies down… assays and lumbar punctures | Alasdair J Coles | 2023/9 | |
Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis | Multiple Sclerosis Journal | Cyrus Daruwalla Vahid Shaygannejad Serkan Ozakbas Eva Kubala Havrdova Dana Horakova | 2023/6 |
095 Remyelination in people with MS due to an RXR agonist is age-dependent | Christopher McMurran Trisha Mukherjee J William Brown Andrew Michell Alasdair Coles | 2022/6/1 | |
Early non-disabling relapses are associated with a higher risk of disability accumulation in people with relapsing-remitting multiple sclerosis | C Daruwalla V Shaygannejad S Ozakbas EK Havrdova R Alroughani | 2022 | |
Case reports in the Lancet: From neurophobia to global pandemics | Clinical case reports | Benjamin O Devoy Peter J Bennett Alasdair J Coles Hani S Mousa | 2022/4 |
Effectiveness of COVID-19 vaccines in multiple sclerosis patients receiving disease-modifying therapies in England | Afagh Garjani Sameer Patel Graham R Law Dhiren Bharkhada Waqar Rashid | 2022/9/1 | |
Diminished seroconversion following a single SARS-COV-2 vaccine in ocrelizumab-treated relapsing-remitting multiple sclerosis patients | Multiple Sclerosis Journal | Zoya G Georgieva Rainer Dӧffinger Dinakantha Kumararatne Alasdair J Coles Claire McCarthy | 2022/6 |
Co-Authors
